This chemical is primarily utilized in the field of targeted protein degradation, specifically as a component of Proteolysis Targeting Chimeras (PROTACs). It is designed to bind selectively to BRD9, a bromodomain-containing protein involved in various cellular processes, including chromatin remodeling and gene transcription. By incorporating this moiety into a PROTAC molecule, it facilitates the recruitment of an E3 ubiquitin ligase to BRD9, leading to its ubiquitination and subsequent degradation by the proteasome. This approach is particularly valuable in research and therapeutic contexts for studying BRD9's biological functions and for potentially treating diseases where BRD9 plays a pathological role, such as certain cancers. Its application enables precise control over protein levels, offering a powerful tool for understanding disease mechanisms and developing targeted therapies.